Live Breaking News & Updates on Tivdak

Stay informed with the latest breaking news from Tivdak on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tivdak and stay connected to the pulse of your community

Second-Line Tivdak 'Very Beneficial' in Cervical Cancer

A phase 3 trial determined that Tivdak showed “game-changing results” for certain patients with cervical cancer, an expert told CURE®.

Florida , United-states , Miami-beach , Brian-slomovitz , Mount-sinai-medical-center , Drug-administration , National-cancer-institute , National-cancer , News , Cervical-cancer , Tivdak , Metastatic-or-recurrent-cervical-cancer

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Emory-university , Georgia , United-states , Atlanta , Susanc-modesitt , National-comprehensive-cancer-network , Winship-cancer-institute-of-emory-university , Onclive-state , Science-summit , Winship-cancer-institute , Gynecologic-oncology

FDA Grants Priority Review to Tisotumab Vedotin sBLA for Recurrent or Metastatic Cervical Cancer

The FDA has granted priority review to a supplemental biologics license application seeking to convert the accelerated approval of tisotumab vedotin to a full approval for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses on or following frontline therapy.

United-states , Pfizer , Seagen-inc , Gynecologic-oncology- , News , Tivdak , Isotumab-vedotin- , Metastatic-cervical-cancer- ,